Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: Immutep Limited ADR (IMMP)

Immutep Ltd (IMMP) - corporate logo

Immutep Limited (IMMP) ensures the stable delivery of clinical test components through global networks, creating innovative methods for combating solid tumors. This daily price action on GURU.Markets based on the EV/EBITDA metric is 0.00. Immutep Limited (IMMP) relies on exclusive rights for LAG-3 protein activation, making it a strategically valuable ally for the world's largest pharmaceutical behemoths.

IMMP Immutep Ltd: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/10/2026

immutep.com - analytical breakdowns and key metrics (IMMP)

- stock price and consensus target price:
Stock Quotes Immutep Limited ADR|IMMP - Consensus Target
- company stock exchange capitalization indicators:
Market Value Immutep Corp|IMMP - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Immutep|IMMP - Company Net Assets|Market Capitalization to Book Value Ratio immutep.com|IMMP - Company Assets
- debt and liquidity data:
Debt to Equity Immutep Limited|IMMP - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Immutep|IMMP - Company Total Debt Obligations|Debt to Book Capitalization Ratio Immutep Corp|IMMP - Company Long-Term Liabilities|Company Short-Term Debt Immutep|Quick Liquidity Indicator immutep.com
- business earnings and investment ratios data:
IMMP - Net Profit|Future Profit Immutep Limited|IMMP - Market Price to Net Income Ratio|Forward P/E Multiple Immutep Limited|IMMP - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immutep Corp|IMMP - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Immutep|IMMP - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months immutep.com|IMMP - Earnings per share growth in current year|Earnings growth forecast for next year Immutep Limited
Comprehensive company analysis:IMMP (Immutep Limited ADR)
Original product of immutep.com

The specifics of Immutep Limited in the development of oncology drugs with international raw material logistics require all debt obligations to be accounted for when assessing value. The multiple compares the total enterprise value with operating profit before depreciation and amortization. A decrease in this ratio signals that assets are undervalued, helping the investor identify an entry point at a discount. Analyzing the current EV/EBITDA multiple allows for the timely recognition of a value trap during a decline in margins.

Competitors of Immutep Limited (IMMP)

Merus Corp - Enterprise Value to EBITDA Ratio|ANIX - Enterprise Value to EBITDA Ratio|ATOS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Context Therapeutics|mersana.com (MRSN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio BriaCell Therapeutics Corp.|EPIX (ESSA Pharma, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA QT Imaging, Inc. QTI